A month has gone by since the last earnings report for DexCom (DXCM). Shares have lost about 3.3% in that time frame, outperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is DexCom due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
DexCom Q4 Earnings and Revenues Surpass Estimates
DexCom, Inc. reported adjusted earnings of $1.15 per share in fourth-quarter 2019, which surpassed the Zacks Consensus Estimate of 75 cents by 53.3%. Moreover, the bottom line soared 105.4% from the prior-year quarter.
Total revenues surged 36.9% to $462.8 million on a year-over-year basis and also beat the Zacks Consensus Estimate by 1.3%. Rising volumes across all channels, strong new patient additions and increasing global awareness of the benefits of real-time CGM contributed to the upside.
2019 at a Glance
In 2019, the company reported revenues worth $1.48 billion, which improved 43.1% from the previous year. The top line also beat the Zacks Consensus Estimate by 2.1%.
Adjusted EPS for the year was $1.84, which improved significantly from that of 2018. The figure also surpassed the consensus mark by 28.7%.
Revenues at the Sensor segment (78% of total revenues) surged 42.2% on a year-over-year basis to $359.5 million. Transmitter revenues (19%) improved 45.9% year over year to $86.1 million. Receiver revenues (4%) declined 34.6% year over year to $17.2 million.
U.S. revenues (81% of total revenues) climbed 33.8% on a year-over-year basis to $375.9 million. International revenues (19%) surged 52.5% year over year to $86.9 million.
Gross profit in the quarter under review totaled $309.3 million, up 38.8% year over year. However, DexCom generated gross margin (as a percentage of revenues) of 66.8%, which expanded 90 bps year over year.
Research and development (R&D) expenses amounted to $78.8 million in the quarter, up 36.8% year over year. Selling, general and administrative expenses totaled $129 million in the reported quarter, up 15.1% year over year.
The company reported total operating expenses of $207.8 million, down 46.4% year over year.
The company reported operating income of $101.5 million, against the year-ago quarter’s operating loss of $164.9 million.
As of Dec 31, 2019, DexCom had $1.53 billion in cash and marketable securities.
Total cash and cash equivalents came in at $446.2 million, which plunged 60.8% from the prior-year quarter.
DexCom expects revenues to range between $1.73 billion and $1.78 billion. The Zacks Consensus Estimate for revenues is currently pegged at $1.75 billion.
Gross profit margin is projected to be around 64% of net revenues.
While adjusted operating margin is expected to be about 13% of net revenues, adjusted EBITDA margin is anticipated to be 23%.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in estimates revision. The consensus estimate has shifted 67.87% due to these changes.
Currently, DexCom has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Estimates have been trending upward for the stock, and the magnitude of this revision has been net zero. It comes with little surprise DexCom has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research